Endocrinology

The protocol appeared safe, with no associated increases in the incidence of hypoglycemic events during hospitalization or 30-day mortality.

The prevalence of NAFLD in the pediatric population has increased in recent years.

The latest endocrine case report features a patient in their mid-40’s with a history of diabetes and recent elbow I&D for an abscess is called back to the ER for wound culture. Can you determine the best treatment strategy?

There are now more insulin options for patients with diabetes than ever before.

Dr. Jabbour discusses unmet needs in diabetes care and starting insulin therapy.

An analysis of more than 100 mother-child pairs from Colorado found children with fetal exposure to cannabis had increased fat mass and fasting glucose levels compared to their counterparts without fetal exposure to cannabis.

On March 29, Antares Pharma announced the FDA granted approval to their oral testosterone replacement therapy option, testosterone udecanoate (TLANDO), for conditions associated with a deficiency or absence of endogenous testosterone or hypogonadism in adult males.

The therapy is indicated for conditions associated with hypogonadism in adult males.

With the newest indication, the GLP-1 agonist is now available in 3 different doses for diabetic adults.

Data from a new study indicates human behavior and decision-making could be hampering the ability of new diabetes technologies to reduce hypoglycemic events in patients with type 1 diabetes.

Severe and level 2 hypoglycemia has continued to occur in individuals with type 1 diabetes and high hypoglycemia risks despite technological advancements.

Children exposed and not exposed to neonatal hypoglycemia did not have significant differences in rates of low educational performance at 9 to 10 years old.

Higher BMI in overweight category at midlife was associated with a greater burden of overall and CVD morbidity, as well as higher health care costs in older adulthood.

A user fee goal date of August 17, 2022 has been assigned to teplizumab.

After a review of the available evidence, the USPSTF concluded there was insufficient evidence to provide recommendations on screening for eating disorders among adults and adolescents.

Data from the PROMISE study provide clinicians with comprehensive insight into the safety and accuracy of the 180-day CGM system from Eversense in patients with diabetes.

After previous studies found an increase in the diagnosis of central precocious puberty, investigators launched a new study to assess whether decreases in physical activity might be linked to the increased diagnosis rate.

A case-control study provides insight into the diagnostic utility of triptorelin-stimulated luteinizing hormone concentrations for diagnosis of central precocious puberty in girls.

Using multiple composite scores to assess dietary quality, investigators use data from 9 NHANES cycles to provide an overview of the declining diet quality among older adults in the US from 2001-2018.

These free resources will help you learn all you need to know about about remote patient monitoring, a digital health solution that captures and records patient physiologic data outside of a traditional health care environment.

Lifestyle interventions had no statistically significant difference in reducing worsening glycemic status compared to usual care in women with gestational diabetes.

The use of GLP-1 receptor agonists was associated with lower all-cause mortality and lower sepsis- and infection-related mortality compared to DPP-4 inhibitors.

An analysis of data from more than 100k pregnant women suggests a history of spontaneous abortion was associated with an 18% increase in risk of subsequent gestational diabetes, with a history of multiple spontaneous abortions associated with an even greater risk.

Dr. Serge Jabbour led the panel in discussing emerging treatments for type 2 diabetes.

Dr. Granger discusses the current underuse of these agents and the steps cardiologists need to take to increase prescription rates and uptake for patients.

A cross-sectional study of more than 70k women suggests those with long or irregular menstrual cycles were at a 22% greater risk of NAFLD.

Announced on March 1, the Breakthrough Device Designation from the FDA allows for use of Dexcom CGM technology in in-hospital settings and at other healthcare facilities.

General progress has been made in decreasing diabetes mortality at ages younger than 25 years, but challenges remain in low and low-middle SDI countries.

Each month, our editorial staff compiles a month in review highlighting the most popular content from the past month. February's month in review features a pair of diabetes tech approvals from the FDA, a video program, and a KOL interview discussing rising death toll attributable to diabetes.

Announced by Reata Pharmaceuticals on February 25, the Complete Response Letter from the FDA for bardoxolone methyl comes a little over 2 months after an FDA advisory committee voted unanimously against approval of the once-daily, orally administered activator of Nrf2.